Neutropenia  >>  Rolvedon (eflapegrastim-xnst) 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rolvedon (eflapegrastim-xnst) / Assertio
NEUTHREE, NCT05949333: Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy

Recruiting
4
100
RoW
Eflapegrastim, Rolvedon, Eflapegrastim-xnst, HM-10460A, SPI-2012
Eunseong Medical Foundation Good GANG-AN HOSPITAL, Hanmi Pharmaceutical Company Limited
Breast Neoplasms
01/25
07/25
NCT04570423: A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Recruiting
2
40
US
Eflapegrastim, Rolontis®, SPI-2012, Chemotherapy
Spectrum Pharmaceuticals, Inc
Solid Tumors, Lymphoma
10/27
10/27
NCT04187898: Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Active, not recruiting
1
50
US
Eflapegrastim, Docetaxel, Taxotere, Cyclophosphamide, Cytoxan
Spectrum Pharmaceuticals, Inc
Neutropenia, Breast Cancer
07/24
07/24

Download Options